Adaptation of the Flag-Ida scheme in the National Cancer Institute: a valuable experience

Dieter Hoelzer, Nicola Gökbuget, Oliver Ottmann, Ching-Hon Pui, Mary V.F Relling, Frederick R. Appelbaum, Jacques J.M. van Dongen, Tomasz Szczepanski. Acute Lymphoblastic Leukemia. Hematology. 2001:162-8.

https://doi.org/10.1182/asheducation-2002.1.162

Jeffrey Szer. The prevalent predicament of relapsed acute myeloid leukemia. Hematology. 2012:43-8.

https://doi.org/10.1182/asheducation.V2012.1.43.3798183

Rowe JM, Goldstone AH. How I treat. Blood. 2007;110:2268-75.

https://doi.org/10.1182/blood-2007-05-038950

de la Rubia J, Regadera A, Martín G, Cervera J, Sanz G, Martínez J, Jarque I, García I, Andreu R, Moscardó F, Jiménez C, Mollá S, Benlloch L, Sanz M. FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patientswith high-risk myeloid malignancies. Leukemia Research. 2002;26:725-30.

https://doi.org/10.1016/S0145-2126(02)00003-6

Jackson GH. Use of fludarabine in the treatment of acute myeloid leukemia. The Hematology Journal. 2004;5 Suppl 1:S62-7.

https://doi.org/10.1038/sj.thj.6200392

Specchia G, Pastore D, Carluccio P, Liso A, Mestice A, Rizzi R, Ciuffreda L, Pietrantuono G, Liso V. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. Ann Hematol. 2005;84:792-5.

https://doi.org/10.1007/s00277-005-1090-9

Milligan DW, Wheatley K, Littlewood T, Craig JI, Burnett AK, NCRI Haematological Oncology Clinical Studies Group. Burnett Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of randomized trial G-CSF and ATRA are not beneficial: results of the MRC AML-HR. Blood. 2006;107:4614-22.

https://doi.org/10.1182/blood-2005-10-4202